Value Of Small Biotech Model In Big Pharma Is Unproven – Former GSK Execs
This article was originally published in The Pink Sheet Daily
GSK’s formation of the Centers of Excellence in Drug Discovery is an example of big pharma “pushing back” on inherent inefficiencies, but the “jury is still out” on large pharmaceutical companies imitating the biotech business model, former execs O’Bryan-Tear and Sorensen say.
You may also be interested in...
Novartis' has unified oncology, transplantation and ophthalmics into one specialty medicine business unit as the company's product mix shifts more toward specialty care
A possible settlement between Merck and tax authorities could be significantly smaller than GlaxoSmithKline's recent settlement with the IRS based on the companies' projected liability
Pfizer's success will depend on its ability to negotiate the paradox of increasing demand for pharmaceuticals coupled with growing attempts to restrain costs, CEO Jeffrey Kindler said